phase readout

NCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

ACTIVE_NOT_RECRUITINGupdated 2mo ago

community read0 votes

Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE1. Conditions: Carcinoma, Renal Cell

Data sources

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?